Santova Full Year 2025 Earnings: EPS: R1.15 (vs R1.12 in FY 2024)
Revenue: R648.9m (down 1.3% from FY 2024).
Net income: R148.1m (flat on FY 2024).
Profit margin: 23% (in line with FY 2024).
EPS: R1.15 (up from R1.12 in FY 2024).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Santova shares are up 1.2% from a week ago.
Before you take the next step you should know about the 1 warning sign for Santova that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
High Growth Tech Stocks To Watch In The US June 2025
Over the last 7 days, the United States market has risen by 2.0% and is up 12% over the past year, with earnings forecasted to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 20.78% 59.46% ★★★★★★ Travere Therapeutics 26.41% 64.47% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Alnylam Pharmaceuticals 23.64% 61.12% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.15% 60.20% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★ Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: AbbVie Inc. is a research-based biopharmaceutical company focused on the development, manufacture, and sale of medicines and therapies globally, with a market capitalization of approximately $328.75 billion. Operations: AbbVie generates revenue primarily from its Innovative Medicines and Therapies segment, which accounts for $57.37 billion. The company is involved in the research, development, manufacture, and sale of biopharmaceutical products worldwide. AbbVie's strategic alliance with the Sarah Cannon Research Institute, announced on May 28, 2025, underscores its commitment to accelerating cancer therapy innovations. This collaboration is expected to enhance clinical trial delivery and drug development efficiency through SCRI's advanced research capabilities. Concurrently, AbbVie's recent FDA approval of EMRELIS™ for specific lung cancer patients highlights its ongoing focus on addressing critical medical needs through targeted therapies. These developments reflect AbbVie's robust investment in R&D which is integral to advancing its pipeline and maintaining competitive advantage in biotech innovation. Get an in-depth perspective on AbbVie's performance by reading our health report here. Explore historical data to track AbbVie's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Fair Isaac Corporation is a company that specializes in developing software with analytics and digital decisioning technologies for global markets, with a market cap of $42.02 billion. Operations: Fair Isaac Corporation generates revenue primarily through its Scores segment, contributing $1.02 billion, and Software segment, which adds $817 million. Fair Isaac Corporation (FICO) is demonstrating robust growth in the tech sector, particularly through its innovative AI solutions that enhance client operations. Recently, FICO has been pivotal for Vitality's Care Hub, revolutionizing healthcare management by integrating digital pathways that reduce operational costs and improve claims processing efficiency. This collaboration underscores FICO's commitment to leveraging technology for transformative business solutions. Financially, FICO is on a strong trajectory with a 13.1% annual revenue growth and an 18% earnings growth forecast, outpacing the US market averages of 8.6% and 14.4%, respectively. Additionally, their strategic use of R&D investment enhances their competitive edge in the high-stakes tech landscape. Dive into the specifics of Fair Isaac here with our thorough health report. Gain insights into Fair Isaac's past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Oracle Corporation provides a range of products and services for enterprise IT environments globally, with a market capitalization of approximately $464.18 billion. Operations: Oracle generates revenue primarily from three segments: Cloud and License ($47.60 billion), Services ($5.26 billion), and Hardware ($2.93 billion). The company's business model focuses on providing comprehensive IT solutions, with a significant portion of its income derived from cloud services and software licensing. Oracle's strategic initiatives in AI and cloud solutions are reshaping its market presence, particularly through its recent partnerships and client engagements. The company's involvement in the Stargate UAE project alongside global tech leaders underscores its commitment to pioneering next-generation AI infrastructures, which is poised to enhance capabilities across various sectors including healthcare and finance. This collaboration not only expands Oracle's technological footprint but also aligns with broader economic development goals by fostering innovation. Moreover, Oracle's R&D investments remain robust, as evidenced by a consistent allocation of resources towards developing cutting-edge technologies. For instance, the company has strategically increased its R&D expenditure to $6.5 billion in 2024 from $6.1 billion the previous year, reflecting a growth of approximately 6.56%. This investment fuels advancements in Oracle's cloud services and software solutions, ensuring that it stays at the forefront of technological innovation and continues to offer competitive services to its clients like Lyntia Networks, enhancing their operational efficiencies through advanced OSS solutions powered by Oracle Communications Cloud Native Suite. Unlock comprehensive insights into our analysis of Oracle stock in this health report. Learn about Oracle's historical performance. Unlock our comprehensive list of 230 US High Growth Tech and AI Stocks by clicking here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABBV NYSE:FICO and NYSE:ORCL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
MicroPort NeuroScientific And 2 Other Undiscovered Gems In Asia
In recent weeks, global markets have been influenced by fluctuating trade policies and economic indicators, with smaller-cap indexes posting positive returns despite lagging behind their larger counterparts. Amid these dynamic conditions, investors may find opportunities in lesser-known stocks that show potential for growth and resilience. When searching for promising investments in the current market environment, it's crucial to focus on companies with strong fundamentals and innovative approaches within their sectors. In this article, we highlight MicroPort NeuroScientific along with two other intriguing small-cap stocks from Asia that could be considered hidden gems. Name Debt To Equity Revenue Growth Earnings Growth Health Rating QuickLtd 0.67% 10.29% 16.51% ★★★★★★ Saha-Union 0.84% 0.90% 15.45% ★★★★★★ Shangri-La Hotel NA 23.33% 39.56% ★★★★★★ Saison Technology NA 1.17% -9.03% ★★★★★★ Grade Upon Technology NA 13.14% 66.01% ★★★★★★ Thai Steel Cable NA 3.84% 18.67% ★★★★★★ Shenzhen Farben Information TechnologyLtd 6.98% 18.64% 2.29% ★★★★★★ Uoriki 0.19% 3.73% 10.97% ★★★★★☆ TSTE 36.22% 3.96% -8.49% ★★★★★☆ Forth Smart Service 51.94% -6.63% -7.91% ★★★★☆☆ Click here to see the full list of 2599 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Value Rating: ★★★★★★ Overview: MicroPort NeuroScientific Corporation focuses on the research, development, production, and sale of neuro-interventional medical devices both in China and internationally, with a market cap of HK$7.06 billion. Operations: The company generates revenue primarily from the sale of surgical and medical equipment, amounting to CN¥761.76 million. MicroPort NeuroScientific, a dynamic player in the medical equipment field, has been making waves with its impressive earnings growth of 74.6% over the past year, significantly outpacing the industry average of 9.6%. The company stands debt-free now compared to five years ago when it had a debt-to-equity ratio of 24.1%, reflecting prudent financial management. Its net income for 2024 reached CNY 254 million, up from CNY 145 million in the previous year, alongside sales climbing to CNY 761 million from CNY 666 million. With high-quality earnings and positive free cash flow trends, MicroPort seems well-positioned for continued growth. Click to explore a detailed breakdown of our findings in MicroPort NeuroScientific's health report. Understand MicroPort NeuroScientific's track record by examining our Past report. Simply Wall St Value Rating: ★★★★★★ Overview: Zhang Jia Gang Freetrade Science & Technology Group Ltd. operates in China through its subsidiaries, focusing on the loading, unloading, and storage of petrochemical products with a market capitalization of CN¥5.84 billion. Operations: The company generates revenue primarily from the loading, unloading, and storage of petrochemical products in China. It has a market capitalization of CN¥5.84 billion. Zhang Jia Gang Freetrade Science & Technology Group, a smaller player in the trade distribution sector, faces challenges with its earnings growth showing a negative trend of 36.1% over the past year. Despite this, it trades at 84.4% below its estimated fair value and has reduced its debt to equity ratio from 22.7% to just 0.2% in five years, indicating effective debt management. The company reported first-quarter sales of CNY 228 million and net income of CNY 30 million, both down from last year's figures of CNY 286 million and CNY 74 million respectively, reflecting ongoing market volatility impacts on performance. Get an in-depth perspective on Zhang Jia Gang Freetrade Science&Technology GroupLtd's performance by reading our health report here. Explore historical data to track Zhang Jia Gang Freetrade Science&Technology GroupLtd's performance over time in our Past section. Simply Wall St Value Rating: ★★★★☆☆ Overview: Luoyang Xinqianglian Slewing Bearing Co., Ltd. specializes in the production of slewing bearings and has a market cap of CN¥12.01 billion. Operations: Luoyang Xinqianglian generates revenue primarily from the sale of slewing bearings. The company's financial performance is highlighted by a gross profit margin that has shown notable variation over recent periods. Luoyang Xinqianglian Slewing Bearing, a notable player in the machinery sector, has shown resilience with its earnings growing 3.2% last year, outpacing the industry's 0.7%. Despite a rise in debt to equity from 31.5% to 57.4% over five years, its net debt to equity ratio remains satisfactory at 37.9%. The company's EBIT covers interest payments well at a ratio of 5.3x, indicating solid financial health despite challenges like reduced net income from CNY 374.84 million to CNY 65.38 million in one year and negative free cash flow trends impacting overall liquidity management strategies. Delve into the full analysis health report here for a deeper understanding of Luoyang Xinqianglian Slewing Bearing. Learn about Luoyang Xinqianglian Slewing Bearing's historical performance. Access the full spectrum of 2599 Asian Undiscovered Gems With Strong Fundamentals by clicking on this link. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2172 SHSE:600794 and SZSE:300850. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
BioNTech (NasdaqGS:BNTX) Enters Global Co-Development Agreement With Bristol Myers Squibb
BioNTech has seen a significant price movement in the past week, with its stock rising by 15%, compared to a 2% increase in the broader market. The recent co-development and co-commercialization agreement between BioNTech and Bristol Myers Squibb for the bispecific antibody BNT327 may have supported this upswing. Additionally, the anticipation surrounding BioNTech's presentations at the ASCO Annual Meeting, showcasing promising clinical trial data, possibly added weight to the positive sentiment. While the market has performed well, these focused developments in BioNTech's oncology pipeline likely provided an additional boost. Buy, Hold or Sell BioNTech? View our complete analysis and fair value estimate and you decide. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. The co-development agreement between BioNTech and Bristol Myers Squibb for the bispecific antibody BNT327, alongside BioNTech's presentations at the ASCO Annual Meeting, could significantly impact its revenue and earnings forecasts. The collaboration and new clinical data may enhance BioNTech's oncology portfolio, potentially driving revenue growth from innovative treatments and first-in-class approvals. Despite this, high R&D expenses and dependency on COVID-19 vaccine sales remain critical risks that could affect financial stability if not offset by new product launches. Over a five-year period, BioNTech has achieved a total return of 134.10%, indicating strong longer-term appreciation. This contrasts with the past year's performance, where the company outperformed the US Biotech industry, which experienced a decline of 13.1%. Despite this favorable long-term total return, the current share price, having climbed 15% recently, still falls short of analyst price targets, suggesting a potential growth opportunity if analyst expectations for the stock materialize. The valuation report we've compiled suggests that BioNTech's current price could be inflated. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:BNTX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
